{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T07:47:14Z","timestamp":1777967234933,"version":"3.51.4"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T00:00:00Z","timestamp":1641859200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Antihypertensive drugs might play a key role in the risk and poor prognosis of colorectal cancer. However, current epidemiologic evidence remains inconsistent. The aim of this study is to quantify the association between antihypertensive drugs and colorectal cancer.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> To identify available studies, we systematically searched electronic databases: PubMed, Web of Science, Embase, Cochrane Library. The risk estimates and their corresponding 95% confidence intervals (CIs) were collected and analyzed by using random-effects models. Heterogeneity test and sensitivity analysis were also performed.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Overall, 37 observational studies were included in this analysis (26 studies with cohort design, three studies with nested case-control design, and 8 studies with case-control design). Antihypertensive drugs did not present a significant effect on the risk or overall survival of patients with colorectal cancer [Risk ratio (RR) = 1.00, 95% CI: 0.95\u20131.04; Hazard ratio (HR) = 0.93, 95% CI: 0.84\u20131.02]. In the subgroup analysis, diuretics use was significantly associated with a worse overall survival of patients with colorectal cancer (HR = 1.27; 95% CI: 1.14\u20131.40). However, use of angiotensin-converting enzyme inhibitors\/angiotensin II receptor blockers was associated with improved progression-free survival of patients who suffered from colorectal cancer (HR = 0.83; 95% CI: 0.72\u20130.95).<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Antihypertensive drug usage did not influence the risk and overall survival of patients with colorectal cancer in general. Further investigation reminded us that diuretics use might reduce the overall survival time in colorectal cancer patients, whereas those who took Angiotensin-converting enzyme inhibitors\/angiotensin II receptor blockers had a longer progression-free survival.<\/jats:p>","DOI":"10.3389\/fphar.2021.670657","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T05:55:04Z","timestamp":1641880504000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Effects of Antihypertensive Drugs Use on Risk and Prognosis of Colorectal Cancer: A Meta-Analysis of 37 Observational Studies"],"prefix":"10.3389","volume":"12","author":[{"given":"Yujiao","family":"Deng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxiu","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bajin","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linghui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lijuan","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1093\/carcin\/bgn171","article-title":"The Renin-Angiotensin System and Malignancy","volume":"29","author":"Ager","year":"2008","journal-title":"Carcinogenesis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1097\/SLA.0000000000002970","article-title":"\u03b2-Blockade in Rectal Cancer Surgery: A Simple Measure of Improving Outcomes","volume":"271","author":"Ahl","year":"2020","journal-title":"Ann. Surg."},{"key":"B3","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1002\/ijc.2910180603","article-title":"Breast Cancer and Use of Rauwolfia and Other Antihypertensive Agents in Hypertensive Patients: a Nationwide Case-Control Study in Finland","volume":"18","author":"Aromaa","year":"1976","journal-title":"Int. J. Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.2174\/1381612825666190111145140","article-title":"The Therapeutic Potential of Angiotensin-Converting Enzyme and Angiotensin Receptor Inhibitors in the Treatment of Colorectal Cancer: Rational Strategies and Recent Progress","volume":"24","author":"Asgharzadeh","year":"2018","journal-title":"Curr. Pharm. Des."},{"key":"B5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/s1470-2045(10)70260-6","article-title":"Antihypertensive Drugs and Risk of Cancer: Network Meta-Analyses and Trial Sequential Analyses of 324,168 Participants from Randomised Trials","volume":"12","author":"Bangalore","year":"2011","journal-title":"Lancet Oncol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating Characteristics of a Rank Correlation Test for Publication Bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/s0959-8049(02)00157-0","article-title":"Verapamil Is Associated with an Increased Risk of Cancer in the Elderly: the Rotterdam Study","volume":"39","author":"Beiderbeck-Noll","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1158\/1055-9965.Epi-08-0095","article-title":"Cardiovascular Medication Use and Risk for Colorectal Cancer","volume":"17","author":"Boudreau","year":"2008","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1186\/s12885-019-5493-8","article-title":"Cardiovascular Medication Use and Risks of colon Cancer Recurrences and Additional Cancer Events: a Cohort Study","volume":"19","author":"Bowles","year":"2019","journal-title":"BMC Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1158\/1055-9965.EPI-20-1401","article-title":"Associations of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use with Colorectal Cancer Risk in the Women's Health Initiative","volume":"30","author":"Brasky","year":"2021","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/1741-7015-12-28","article-title":"Drugs Affecting the Renin-Angiotensin System and Survival from Cancer: a Population Based Study of Breast, Colorectal and Prostate Cancer Patient Cohorts","volume":"12","author":"Cardwell","year":"2014","journal-title":"BMC Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e1097","DOI":"10.1097\/md.0000000000001097","article-title":"Propranolol Reduces Cancer Risk: A Population-Based Cohort Study","volume":"94","author":"Chang","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1161\/HYPERTENSIONAHA.120.15317","article-title":"ACE (Angiotensin-Converting Enzyme) Inhibitors\/Angiotensin Receptor Blockers Are Associated with Lower Colorectal Cancer Risk: A Territory-wide Study with Propensity Score Analysis","volume":"76","author":"Cheung","year":"2020","journal-title":"Hypertension"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1002\/ijc.25234","article-title":"Deficiency or Blockade of Angiotensin II Type 2 Receptor Delays Tumorigenesis by Inhibiting Malignant Cell Proliferation and Angiogenesis","volume":"127","author":"Clere","year":"2010","journal-title":"Int. J. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1093\/aje\/kwz106","article-title":"Use of Antihypertensive Medications and Survival Rates for Breast, Colorectal, Lung, or Stomach Cancer","volume":"188","author":"Cui","year":"2019","journal-title":"Am. J. Epidemiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/s0140-6736(19)32319-0","article-title":"Colorectal Cancer","volume":"394","author":"Dekker","year":"2019","journal-title":"The Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"690663","DOI":"10.3389\/fnut.2021.690663","article-title":"Dietary Risk-Related Colorectal Cancer Burden: Estimates from 1990 to 2019","volume":"8","author":"Deng","year":"2021","journal-title":"Front. Nutr."},{"key":"B18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ypmed.2017.01.011","article-title":"Relationship between Drugs Affecting the Renin-Angiotensin System and Colorectal Cancer: The MCC-Spain Study","volume":"99","author":"Dierssen-Sotos","year":"2017","journal-title":"Prev. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in Meta-Analysis Detected by a Simple, Graphical Test","volume":"315","author":"Egger","year":"1997","journal-title":"Bmj"},{"key":"B20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/s0140-6736(15)01225-8","article-title":"Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: a Systematic Review and Meta-Analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3390\/cancers11121856","article-title":"Incidental Use of Beta-Blockers Is Associated with Outcome of Metastatic Colorectal Cancer Patients Treated with Bevacizumab-Based Therapy: A Single-Institution Retrospective Analysis of 514 Patients","volume":"11","author":"Fiala","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/ijc.25351","article-title":"Norepinephrine Antagonists and Cancer Risk","volume":"128","author":"Friedman","year":"2011","journal-title":"Int. J. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/nrc2945","article-title":"The Renin-Angiotensin System and Cancer: Old Dog, New Tricks","volume":"10","author":"George","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e719","DOI":"10.1097\/MD.0000000000000719","article-title":"Prognostic Value for Incidental Antihypertensive Therapy with Beta-Blockers in Metastatic Colorectal Cancer","volume":"94","author":"Giampieri","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41416-020-0751-8","article-title":"T-type Calcium Channel Inhibition Restores Sensitivity to MAPK Inhibitors in De-differentiated and Adaptive Melanoma Cells","volume":"122","author":"Granados","year":"2020","journal-title":"Br. J. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11906-002-0054-x","article-title":"Microvascular Angiogenesis and the Renin-Angiotensin System","volume":"4","author":"Greene","year":"2002","journal-title":"Curr. Hypertens. Rep."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e009147","DOI":"10.1136\/bmjopen-2015-009147","article-title":"Calcium Channel Blockers and Cancer: a Risk Analysis Using the UK Clinical Practice Research Datalink (CPRD)","volume":"6","author":"Grimaldi-Bensouda","year":"2016","journal-title":"BMJ Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1053\/euhj.2001.2729","article-title":"Antihypertensive Therapy and the Risk of Malignancies","volume":"22","author":"Grossman","year":"2001","journal-title":"Eur. Heart J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/ajh.2010.105","article-title":"Ethnic Differences in Blood Pressure Response to First and Second-Line Antihypertensive Therapies in Patients Randomized in the ASCOT Trial","volume":"23","author":"Gupta","year":"2010","journal-title":"Am. J. Hypertens."},{"key":"B30","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1111\/j.1365-2125.2012.04170.x","article-title":"Long Term Use of Drugs Affecting the Renin-Angiotensin System and the Risk of Cancer: a Population-Based Case-Control Study","volume":"74","author":"Hallas","year":"2012","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1093\/annonc\/mdt381","article-title":"\u03b2-Blocker Usage and Colorectal Cancer Mortality: A Nested Case-Control Study in the UK Clinical Practice Research Datalink Cohort","volume":"24","author":"Hicks","year":"2013","journal-title":"Ann. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.canep.2013.09.001","article-title":"Antihypertensive Medications and Survival in Patients with Cancer: A Population-Based Retrospective Cohort Study","volume":"37","author":"Holmes","year":"2013","journal-title":"Cancer Epidemiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/annonc\/mdt372","article-title":"Potential Increased Risk of Cancer from Commonly Used Medications: an Umbrella Review of Meta-Analyses","volume":"25","author":"Ioannidis","year":"2014","journal-title":"Ann. Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1002\/cncr.26727","article-title":"Beta Blocker Use and Colorectal Cancer Risk: Population-Based Case-Control Study","volume":"118","author":"Jansen","year":"2012","journal-title":"Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/cncr.28546","article-title":"Stage-specific Associations between Beta Blocker Use and Prognosis after Colorectal Cancer","volume":"120","author":"Jansen","year":"2014","journal-title":"Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ijc.30717","article-title":"Pre- and post-diagnostic Beta-Blocker Use and Prognosis after Colorectal Cancer: Results from a Population-Based Study","volume":"141","author":"Jansen","year":"2017","journal-title":"Int. J. Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"7660","DOI":"10.1158\/0008-5472.Can-05-0275","article-title":"Angiotensin II Type 2 Receptor Gene Deficiency Attenuates Susceptibility to Tobacco-specific Nitrosamine-Induced Lung Tumorigenesis: Involvement of Transforming Growth Factor-beta-dependent Cell Growth Attenuation","volume":"65","author":"Kanehira","year":"2005","journal-title":"Cancer Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ijcard.2015.02.015","article-title":"Carvedilol Use Is Associated with Reduced Cancer Risk: A Nationwide Population-Based Cohort Study","volume":"184","author":"Lin","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR Effect for Macromolecular Drug Delivery to Solid Tumors: Improvement of Tumor Uptake, Lowering of Systemic Toxicity, and Distinct Tumor Imaging In Vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"6527457","DOI":"10.1155\/2019\/6527457","article-title":"Impact of Metabolic Syndrome Diagnosis and its Treatment on Survival of Colorectal Cancer Patients","volume":"2019","author":"Mafiana","year":"2019","journal-title":"J. Cancer Epidemiol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"djt374","DOI":"10.1093\/jnci\/djt374","article-title":"Angiotensin-converting Enzyme Inhibitor Therapy and Colorectal Cancer Risk","volume":"106","author":"Makar","year":"2014","journal-title":"J. Natl. Cancer Inst."},{"key":"B42","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/bjc.2013.292","article-title":"The Impact of Aspirin, Statins and ACE-Inhibitors on the Presentation of Colorectal Neoplasia in a Colorectal Cancer Screening Programme","volume":"109","author":"Mansouri","year":"2013","journal-title":"Br. J. Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","article-title":"Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Cancer Progression and Survival: a Systematic Review","volume":"23","author":"Mc Menamin \u00da","year":"2012","journal-title":"Cancer Causes Control"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.15585\/mmwr.mm6545a3","article-title":"CDC Grand Rounds: A Public Health Approach to Detect and Control Hypertension","volume":"65","author":"Merai","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1002\/(sici)1097-0142(19981101)83:9<2003:aid-cncr17>3.0.co;2-3","article-title":"Calcium Channel Blockers, Cancer Incidence, and Cancer Mortality in a Cohort of U.S. Women: the Nurses' Health Study","volume":"83","author":"Michels","year":"1998","journal-title":"Cancer"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1136\/bmj.b2535","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"Plos Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1002\/cncr.30079","article-title":"Increased Tumor Response to Neoadjuvant Therapy Among Rectal Cancer Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers","volume":"122","author":"Morris","year":"2016","journal-title":"Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1097\/cej.0000000000000218","article-title":"Adrenergic Blockers and the Risk for Common Solid Cancers: a Case-Control Study","volume":"26","author":"Numbere","year":"2015","journal-title":"Eur. J. Cancer Prev."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.jacc.2015.07.021","article-title":"Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in Hypertensive Blacks versus Whites","volume":"66","author":"Ogedegbe","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.3892\/mco.2015.630","article-title":"Angiotensin II Type-1 Receptor Blockers Enhance the Effects of Bevacizumab-Based Chemotherapy in Metastatic Colorectal Cancer Patients","volume":"3","author":"Osumi","year":"2015","journal-title":"Mol. Clin. Oncol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1007\/s00384-019-03379-y","article-title":"Angiotensin I-Converting Enzyme Inhibitors\/angiotensin II Receptor Blockers May Reduce Tumor Recurrence in Left-Sided and Early Colorectal Cancers","volume":"34","author":"Ozawa","year":"2019","journal-title":"Int. J. Colorectal Dis."},{"key":"B52","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/s0140-6736(96)04277-8","article-title":"Calcium-channel Blockade and Incidence of Cancer in Aged Populations","volume":"348","author":"Pahor","year":"1996","journal-title":"The Lancet"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/jama.279.13.1000","article-title":"Calcium Channel Blockers and the Risk of Cancer","volume":"279","author":"Rosenberg","year":"1998","journal-title":"J. Am. Med. Assoc."},{"key":"B54","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/s1470-2045(10)70106-6","article-title":"Angiotensin-receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials","volume":"11","author":"Sipahi","year":"2010","journal-title":"Lancet Oncol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/1097-0142(20000701)89:1<165:Aid-cncr21>3.0.Co;2-g","article-title":"Cancer Risk and Mortality in Users of Calcium Channel Blockers - A Cohort Study","volume":"89","author":"Sorensen","year":"2000","journal-title":"Cancer"},{"key":"B56","first-page":"817","article-title":"Rauwolfia Use and Breast Cancer: a Case-Control Study","volume":"76","author":"Stanford","year":"1986","journal-title":"J. Natl. Cancer Inst."},{"key":"B57","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.3747\/co.25.4069","article-title":"Hypertension as a Predictor of Advanced Colorectal Cancer Outcome and Cetuximab Treatment Response","volume":"25","author":"Sud","year":"2018","journal-title":"Curr. Oncol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"B59","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.semcancer.2013.08.009","article-title":"\u03b2-Adrenergic System, a Backstage Manipulator Regulating Tumour Progression and Drug Target in Cancer Therapy","volume":"23","author":"Tang","year":"2013","journal-title":"Semin. Cancer Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/sj.jhh.1001192","article-title":"Long-term Diuretic Therapy in Patients with Coronary Disease: Increased colon Cancer-Related Mortality over a 5-year Follow-Up","volume":"15","author":"Tenenbaum","year":"2001","journal-title":"J. Hum. Hypertens."},{"key":"B61","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/hjh.0000000000000447","article-title":"Effects of Blood Pressure Lowering on Outcome Incidence in Hypertension: 4. Effects of Various Classes of Antihypertensive Drugs-Ooverview and Meta-Analyses","volume":"33","author":"Thomopoulos","year":"2015","journal-title":"J. Hypertens."},{"key":"B62","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/cncr.23215","article-title":"Renin-anglotensin System Inhibitors, Angiotensin I-Converting Enzyme Gene Insertion\/deletion Polymorphism, and Cancer","volume":"112","author":"van der Knaap","year":"2008","journal-title":"Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.ijcard.2012.05.096","article-title":"Long-term Use of Angiotensin II Receptor Blockers and Risk of Cancer: a Population-Based Cohort Analysis","volume":"167","author":"Wang","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10654-017-0304-5","article-title":"Immortal Time Bias in Pharmacoepidemiological Studies on Cancer Patient Survival: Empirical Illustration for Beta-Blocker Use in Four Cancers with Different Prognosis","volume":"32","author":"Weberpals","year":"2017","journal-title":"Eur. J. Epidemiol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e19075","DOI":"10.1097\/MD.0000000000019075","article-title":"The Renin-Angiotensin System Blockers and Survival in Digestive System Malignancies: A Systematic Review and Meta-Analysis","volume":"99","author":"Zhou","year":"2020","journal-title":"Medicine (Baltimore)"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.670657\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T05:55:12Z","timestamp":1641880512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.670657\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,11]]},"references-count":65,"alternative-id":["10.3389\/fphar.2021.670657"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.670657","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,11]]},"article-number":"670657"}}